shigella sonnei vaccine (GSK3536852)
/ GSK, Bharat Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 18, 2020
A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
(clinicaltrials.gov)
- P2; N=71; Completed; Sponsor: GlaxoSmithKline; Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 1
Of
1
Go to page
1